<?xml version="1.0" encoding="UTF-8"?>
<p>Safety was defined primarily as the absence of treatment‐related serious adverse events (SAEs), assessed according to the Consolidated Standards of Reporting Trials 
 <xref rid="sct312351-bib-0025" ref-type="ref">25</xref>, and secondarily as the absence of dose‐limiting toxicity, defined as death within 6 hours after MSC transplantation, or anaphylactic shock related to the administration of MSCs. After a single intraventricular transplantation of MSCs, all patients were regularly and intensively assessed until either 36–40 weeks of corrected gestational age, or first discharge from NICU, whichever occurred first.
</p>
